Robert F Garry

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5116323/publications.pdf

Version: 2024-02-01

239 papers	15,749 citations	38742 50 h-index	22166 113 g-index
247 all docs	247 docs citations	247 times ranked	20708 citing authors

#	Article	IF	Citations
1	Ebola virus delta peptide is an enterotoxin. Cell Reports, 2022, 38, 110172.	6.4	3
2	Enterotoxigenic Escherichia coli Heat-Stable Toxin and Ebola Virus Delta Peptide: Similarities and Differences. Pathogens, 2022, 11, 170.	2.8	0
3	Authors' Reply. Journal of Molecular Diagnostics, 2022, 24, 103.	2.8	0
4	Role of the T cell vitamin D receptor in severe COVID-19. Nature Immunology, 2022, 23, 5-6.	14.5	9
5	Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. Cell Reports, 2022, 39, 110841.	6.4	17
6	Neutralizing Antibodies against Lassa Virus Lineage I. MBio, 2022, 13, .	4.1	12
7	Lassa Fever among Children in Eastern Province, Sierra Leone: A 7-year Retrospective Analysis (2012â€“2018). American Journal of Tropical Medicine and Hygiene, 2021, 104, 585-592.	1.4	12
8	Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012â€“2019. Microorganisms, 2021, 9, 586.	3.6	10
9	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity, 2021, 54, 815-828.e5.	14.3	34
10	Post-Ebola Syndrome Presents With Multiple Overlapping Symptom Clusters: Evidence From an Ongoing Cohort Study in Eastern Sierra Leone. Clinical Infectious Diseases, 2021, 73, 1046-1054.	5.8	15
11	Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail. Viruses, 2021, 13, 1202.	3.3	26
12	Implementation of the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: Lessons learned for vision health systems strengthening in Sierra Leone. PLoS ONE, 2021, 16, e0252905.	2.5	5
13	After the pandemic: perspectives on the future trajectory of COVID-19. Nature, 2021, 596, 495-504.	27.8	260
14	Health seeking behavior after the 2013â€“16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. PLoS Neglected Tropical Diseases, 2021, 15, e0009576.	3.0	8
15	The Origins and Future of Sentinel: An Early-Warning System for Pandemic Preemption and Response. Viruses, 2021, 13, 1605.	3.3	8
16	Ct Values Do Not Predict Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmissibility in College Students. Journal of Molecular Diagnostics, 2021, 23, 1078-1084.	2.8	29
17	Emergence of an early SARS-CoV-2 epidemic in the United States. Cell, 2021, 184, 4939-4952.e15.	28.9	31
18	Posterior Segment Ophthalmic Manifestations in Ebola Survivors, Sierra Leone. Ophthalmology, 2021, 128, 1371-1373.	5.2	5

#	Article	IF	Citations
19	The origins of SARS-CoV-2: A critical review. Cell, 2021, 184, 4848-4856.	28.9	330
20	Zika Virus Non-Structural Protein 1 Antigen-Capture Immunoassay. Viruses, 2021, 13, 1771.	3.3	5
21	Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. Viruses, 2021, 13, 2325.	3.3	24
22	289. Post COVID Syndrome Cohort Characterization. Open Forum Infectious Diseases, 2021, 8, S251-S252.	0.9	0
23	Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever. Emerging Infectious Diseases, 2020, 26, 2625-2637.	4.3	13
24	Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Scientific Reports, 2020, 10, 16030.	3.3	15
25	Elevated l-threonine is a biomarker for Lassa fever and Ebola. Virology Journal, 2020, 17, 188.	3.4	7
26	From Kenema to Our Krios: Medical Defense Against Lassa Virus and Emerging Infectious Disease. Microscopy and Microanalysis, 2020, 26, 568-568.	0.4	0
27	Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides. Journal of Virology, 2020, 94, .	3.4	16
28	Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time. Nature Communications, 2020, 11, 4131.	12.8	101
29	Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses. Journal of Infectious Diseases, 2020, 221, 156-161.	4.0	35
30	50ÂYears of Lassa Fever Research. Current Topics in Microbiology and Immunology, 2020, , 1-22.	1.1	4
31	The proximal origin of SARS-CoV-2. Nature Medicine, 2020, 26, 450-452.	30.7	3,871
32	High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathogens, 2020, 16, e1008352.	4.7	22
33	Proteomics Computational Analyses Suggest that the Envelope Glycoproteins of Segmented Jingmen Flavi-Like Viruses Are Class II Viral Fusion Proteins (Î²-Penetrenes) with Mucin-Like Domains. Viruses, 2020, 12, 260.	3.3	13
34	Identification of Common CD8⁺T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone. Journal of Virology, 2020, 94, .	3.4	15
35	Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. Scientific Reports, 2020, 10, 8724.	3.3	14
36	Ebola-Specific CD8+ and CD4+ T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae. Journal of Infectious Diseases, 2020, 222, 1488-1497.	4.0	13

#	Article	IF	Citations
37	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
38	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
39	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
40	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
41	Ebola Mysteries and Conundrums. Journal of Infectious Diseases, 2019, 219, 511-513.	4.0	0
42	Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization. Cell, 2019, 178, 1004-1015.e14.	28.9	39
43	Antibody therapy for Lassa fever. Current Opinion in Virology, 2019, 37, 97-104.	5.4	28
44	Proteomics Computational Analyses Suggest that the Antennavirus Glycoprotein Complex Includes a Class I Viral Fusion Protein (Î±-Penetrene) with an Internal Zinc-Binding Domain and a Stable Signal Peptide. Viruses, 2019, 11, 750.	3.3	8
45	2018 international meeting of the Global Virus Network. Antiviral Research, 2019, 163, 140-148.	4.1	9
46	Machine-learning Prognostic Models from the 2014â€“16 Ebola Outbreak: Data-harmonization Challenges, Validation Strategies, and mHealth Applications. EClinicalMedicine, 2019, 11, 54-64.	7.1	38
47	Data set on Lassa fever in post-conflict Sierra Leone. Data in Brief, 2019, 23, 103673.	1.0	12
48	A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. PLoS ONE, 2019, 14, e0214284.	2.5	14
49	Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Scientific Reports, 2018, 8, 5939.	3.3	39
50	Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors. Journal of Proteome Research, 2018, 18, 7-17.	3.7	7
51	Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. New England Journal of Medicine, 2018, 379, 1745-1753.	27.0	135
52	Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. EBioMedicine, 2018, 30, 217-224.	6.1	42
53	Early detection of Lassa fever: the need for point-of-care diagnostics. Lancet Infectious Diseases, The, 2018, 18, 601-602.	9.1	6
54	Analysis of CD8 ⁺ T cell response during the 2013â€“2016 Ebola epidemic in West Africa. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7578-E7586.	7.1	55

#	Article	IF	Citations
55	Annual Incidence of Lassa Virus Infection in Southern Mali. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0821.	1.4	14
56	Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature, 2017, 544, 309-315.	27.8	346
57	Genomic epidemiology reveals multiple introductions of Zika virus into the United States. Nature, 2017, 546, 401-405.	27.8	298
58	Structural basis for antibody-mediated neutralization of Lassa virus. Science, 2017, 356, 923-928.	12.6	170
59	Ebola Virus Delta Peptide Is a Viroporin. Journal of Virology, 2017, 91, .	3.4	26
60	Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nature Medicine, 2017, 23, 1146-1149.	30.7	95
61	How to turn competitors into collaborators. Nature, 2017, 541, 283-285.	27.8	3
62	Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers. PLoS Neglected Tropical Diseases, 2017, 11, e0005943.	3.0	17
63	Vectorborne Infections, Mali. Emerging Infectious Diseases, 2016, 22, 340-342.	4.3	20
64	Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. Emerging Infectious Diseases, 2016, 22, 657-663.	4.3	26
65	Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. Viruses, 2016, 8, 150.	3.3	64
66	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. Journal of Infectious Diseases, 2016, 214, S110-S121.	4.0	34
67	Roots, Not Parachutes: Research Collaborations Combat Outbreaks. Cell, 2016, 166, 5-8.	28.9	48
68	Ebola Virus Epidemiology and Evolution in Nigeria. Journal of Infectious Diseases, 2016, 214, S102-S109.	4.0	19
69	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nature Communications, 2016, 7, 11544.	12.8	148
70	Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV. Nature Structural and Molecular Biology, 2016, 23, 513-521.	8.2	65
71	Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, S210-S217.	4.0	35
72	Overlooking the importance of immunoassays. Lancet Infectious Diseases, The, 2016, 16, 1109-1110.	9.1	4

#	Article	IF	Citations
73	Treatment of Lassa virus infection in outbred guinea pigs with first-in-classÂhuman monoclonal antibodies. Antiviral Research, 2016, 133, 218-222.	4.1	57
74	Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, S203-S209.	4.0	29
75	Epidemiology and Management of the 2013â€“16 West African Ebola Outbreak. Annual Review of Virology, 2016, 3, 147-171.	6.7	28
76	A Unified Framework for the Infection Dynamics of Zoonotic Spillover and Spread. PLoS Neglected Tropical Diseases, 2016, 10, e0004957.	3.0	52
77	IFN-Î» Inhibits MiR-122 Transcription through a Stat3-HNF4Î± Inflammatory Feedback Loop in an IFN-Î± Resistant HCV Cell Culture System. PLoS ONE, 2015, 10, e0141655.	2.5	13
78	Development of Prototype Filovirus Recombinant Antigen Immunoassays. Journal of Infectious Diseases, 2015, 212, S359-S367.	4.0	30
79	Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virology, 2015, 10, 559-584.	1.8	18
80	Multiple Circulating Infections Can Mimic the Early Stages of Viral Hemorrhagic Fevers and Possible Human Exposure to Filoviruses in Sierra Leone Prior to the 2014 Outbreak. Viral Immunology, 2015, 28, 19-31.	1.3	33
81	Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone. Cell, 2015, 161, 1516-1526.	28.9	275
82	Modeling of the Ebola Virus Delta Peptide Reveals a Potential Lytic Sequence Motif. Viruses, 2015, 7, 285-305.	3.3	18
83	Discovery of Novel Rhabdoviruses in the Blood of Healthy Individuals from West Africa. PLoS Neglected Tropical Diseases, 2015, 9, e0003631.	3.0	56
84	Using Modelling to Disentangle the Relative Contributions of Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever. PLoS Neglected Tropical Diseases, 2015, 9, e3398.	3.0	96
85	Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell, 2015, 162, 738-750.	28.9	230
86	Ebola control: rapid diagnostic testing. Lancet Infectious Diseases, The, 2015, 15, 147-148.	9.1	38
87	Persistent Hepatitis C Virus Infection Impairs Ribavirin Antiviral Activity through Clathrin-Mediated Trafficking of Equilibrative Nucleoside Transporter 1. Journal of Virology, 2015, 89, 626-642.	3.4	20
88	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	3.3	49
89	Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses, 2014, 6, 4760-4799.	3.3	83
90	Lassa Fever in Post-Conflict Sierra Leone. PLoS Neglected Tropical Diseases, 2014, 8, e2748.	3.0	172

#	Article	IF	Citations
91	Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples. Genome Biology, 2014, 15, 519.	8.8	129
92	Inhibition of Arenavirus Infection by a Glycoprotein-Derived Peptide with a Novel Mechanism. Journal of Virology, 2014, 88, 8556-8564.	3.4	15
93	Clinical Illness and Outcomes in Patients with Ebola in Sierra Leone. New England Journal of Medicine, 2014, 371, 2092-2100.	27.0	471
94	Unexpected Structural Features of the Hepatitis C Virus Envelope Protein 2 Ectodomain. Journal of Virology, 2014, 88, 10280-10288.	3.4	37
95	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361
96	Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science, 2014, 345, 1369-1372.	12.6	1,083
97	A tribute to Sheik Humarr Khan and all the healthcare workers in West Africa who have sacrificed in the fight against Ebola virus disease: Mae we hush. Antiviral Research, 2014, 111, 33-35.	4.1	19
98	Peptide entry inhibitors of enveloped viruses: The importance of interfacial hydrophobicity. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2180-2197.	2.6	120
99	Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. PLoS Neglected Tropical Diseases, 2013, 7, e2582.	3.0	49
100	A Fusion-Inhibiting Peptide against Rift Valley Fever Virus Inhibits Multiple, Diverse Viruses. PLoS Neglected Tropical Diseases, 2013, 7, e2430.	3.0	30
101	Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation. PLoS ONE, 2013, 8, e72791.	2.5	13
102	Emerging Disease or Diagnosis?. Science, 2012, 338, 750-752.	12.6	29
103	Topical vitamin A treatment of recalcitrant common warts. Virology Journal, 2012, 9, 21.	3.4	15
104	Release of Dengue Virus Genome Induced by a Peptide Inhibitor. PLoS ONE, 2012, 7, e50995.	2.5	71
105	Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: Case Report. Virology Journal, 2011, 8, 314.	3.4	41
106	Mechanism of HCV's resistance to IFN-Î± in cell culture involves expression of functional IFN-Î± receptor 1. Virology Journal, 2011, 8, 351.	3.4	15
107	Lassa hemorrhagic fever in a late term pregnancy from northern sierra leone with a positive maternal outcome: case report. Virology Journal, 2011, 8, 404.	3.4	53
108	Sequence similarity between the erythrocyte binding domain 1 of the Plasmodium vivax Duffy binding protein and the V3 loop of HIV-1 strain MN reveals binding residues for the Duffy Antigen Receptor for Chemokines. Virology Journal, 2011, 8, 45.	3.4	6

#	Article	IF	Citations
109	Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virology Journal, 2011, 8, 478.	3.4	69
110	Sequence similarity between the erythrocyte binding domain of the Plasmodium vivax Duffy binding protein and the V3 loop of HIV-1 strain MN reveals a functional heparin binding motif involved in binding to the Duffy antigen receptor for chemokines. Virology Journal, 2011, 8, 523.	3.4	5
111	Peptide inhibition of human cytomegalovirus infection. Virology Journal, 2011, 8, 76.	3.4	20
112	The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology, 2010, 407, 110-119.	2.4	17
113	Detection of Lassa Virus, Mali. Emerging Infectious Diseases, 2010, 16, 1123-1126.	4.3	89
114	Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virology Journal, 2010, 7, 118.	3.4	14
115	Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication. Virology Journal, 2010, 7, 265.	3.4	14
116	Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virology Journal, 2010, 7, 279.	3.4	77
117	Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects. Virology Journal, 2010, 7, 306.	3.4	23
118	Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virology Journal, 2010, 7, 36.	3.4	25
119	Altered Immune Responses in Rhesus Macaques Co-Infected with SIV and Plasmodium cynomolgi: An Animal Model for Coincident AIDS and Relapsing Malaria. PLoS ONE, 2009, 4, e7139.	2.5	18
120	Proteomics computational analyses suggest that the bornavirus glycoprotein is a class III viral fusion protein (Î³ penetrene). Virology Journal, 2009, 6, 145.	3.4	13
121	Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. Virology Journal, 2009, 6, 147.	3.4	14
122	New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Research, 2008, 78, 103-115.	4.1	156
123	Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding. Virology Journal, 2008, 5, 161.	3.4	18
124	Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virology Journal, 2008, 5, 74.	3.4	24
125	Alterations in intracellular potassium concentration by HIV-1 and SIV Nef. Virology Journal, 2008, 5, 60.	3.4	11
126	Proteomics computational analyses suggest that baculovirus GP64 superfamily proteins are class III penetrenes. Virology Journal, 2008, 5, 28.	3.4	21

#	Article	IF	Citations
127	Down-regulation of cell surface CXCR4 by HIV-1. Virology Journal, 2008, 5, 6.	3.4	4
128	Mechanisms of Interferon Action and Resistance in Chronic Hepatitis C Virus Infection: Lessons Learned from Cell Culture Studies. , 2008, , 16-38.		0
129	Lassa Virus-Infected Rodents in Refugee Camps in Guinea: A Looming Threat to Public Health in a Politically Unstable Region. Vector-Borne and Zoonotic Diseases, 2007, 7, 167-171.	1.5	17
130	Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein. Virology Journal, 2007, 4, 123.	3.4	33
131	Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon. Virology Journal, 2007, 4, 89.	3.4	21
132	An invitation to recent graduates: Publish your dissertation/thesis background section as a review in Virology Journal. Virology Journal, 2007, 4, 46.	3.4	0
133	Aluminum Adjuvant Linked to Gulf War Illness Induces Motor Neuron Death in Mice. NeuroMolecular Medicine, 2007, 9, 83-100.	3.4	93
134	Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes. Virology Journal, 2006, 3, 100.	3.4	43
135	Role of Endogenous Retroviruses in Autoimmune Diseases. Infectious Disease Clinics of North America, 2006, 20, 913-929.	5.1	27
136	Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Research, 2006, 120, 146-155.	2.2	66
137	Musculoskeletal and autoimmune manifestations of HIV, syphilis and tuberculosis. Current Opinion in Rheumatology, 2006, 18, 88-95.	4.3	18
138	Synergistic Inhibition of Sars-Coronavirus Replication by Type I and Type II IFN. Advances in Experimental Medicine and Biology, 2006, 581, 503-506.	1.6	11
139	Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation.. Liver International, 2005, 25, 580-594.	3.9	31
140	Safe method for isolation of prion protein and diagnosis of Creutzfeldtâ€“Jakob disease. Journal of Virological Methods, 2005, 130, 133-139.	2.1	7
141	Seroreactivity to A-type retrovirus proteins in a subset of cats with hyperthyroidism. Microscopy Research and Technique, 2005, 68, 235-238.	2.2	3
142	Dengue in the Dominican Republic: Epidemiology for 2004. Microscopy Research and Technique, 2005, 68, 250-254.	2.2	4
143	HCVâ€hepatocellular carcinoma: New findings and hope for effective treatment. Microscopy Research and Technique, 2005, 68, 130-148.	2.2	13
144	Alterations of lymphocyte membranes during HIV-1 infection via multiple and simultaneous entry strategies. Microscopy Research and Technique, 2005, 68, 149-167.	2.2	3

#	Article	IF	Citations
145	Of mice, cats, and men: Is human breast cancer a Zoonosis?. Microscopy Research and Technique, 2005, 68, 197-208.	2.2	35
146	Human, rhesus macaque, and feline sequences highly similar to mouse mammary tumor virus sequences. Microscopy Research and Technique, 2005, 68, 209-221.	2.2	23
147	Involvement of human intracisternal A-type retroviral particles in autoimmunity. Microscopy Research and Technique, 2005, 68, 222-234.	2.2	15
148	Introduction to special issue: Viruses and neoplasia. Microscopy Research and Technique, 2005, 68, 115-119.	2.2	0
149	Activation of Interferon-Stimulated Response Element in Huh-7 Cells Replicating Hepatitis C Virus Subgenomic RNA. Intervirology, 2005, 48, 301-311.	2.8	10
150	Identification and Characterization of the Putative Fusion Peptide of the Severe Acute Respiratory Syndrome-Associated Coronavirus Spike Protein. Journal of Virology, 2005, 79, 7195-7206.	3.4	126
151	Peptide inhibitors of dengue virus and West Nile virus infectivity. Virology Journal, 2005, 2, 49.	3.4	155
152	The Aromatic Domain of the Coronavirus Class I Viral Fusion Protein Induces Membrane Permeabilization:Â Putative Role during Viral Entryâ€. Biochemistry, 2005, 44, 947-958.	2.5	58
153	Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe hemophiliac sera. Virology Journal, 2005, 2, 65.	3.4	10
154	Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virology Journal, 2005, 2, 14.	3.4	64
155	Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes. Journal of General Virology, 2005, 86, 3047-3053.	2.9	18
156	Treatment of Warts. New England Journal of Medicine, 2004, 351, 1692-1693.	27.0	5
157	Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology, 2004, 329, 11-17.	2.4	162
158	Interferon alpha-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone. Experimental and Molecular Pathology, 2004, 76, 242-252.	2.1	23
159	Linking chronic wasting disease to scrapie by comparison of Spiroplasma mirum ribosomal DNA sequences. Experimental and Molecular Pathology, 2004, 77, 49-56.	2.1	38
160	Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes). , 2004, 1, 10.		97
161	Virology on the Internet: the time is right for a new journal. Virology Journal, 2004, 1, 1.	3.4	5
162	Inhibition of Hepatitis C Virus Nonstructural Protein, Helicase Activity, and Viral Replication by a Recombinant Human Antibody Clone. American Journal of Pathology, 2004, 165, 1163-1173.	3.8	24

#	Article	IF	Citations
163	Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies. Journal of Clinical Virology, 2004, 31, 190-197.	3.1	11
164	Stem-loop structures II-IV of the 5? untranslated sequences are required for the expression of the full-length hepatitis C virus genome. Archives of Virology, 2003, 148, 449-467.	2.1	12
165	Expression of granzyme B mRNA is altered in human immunodeficiency virus infected patients. Experimental and Molecular Pathology, 2003, 74, 13-16.	2.1	2
166	A heparin binding synthetic peptide from human HIP / RPL29 fails to specifically differentiate between anticoagulantly active and inactive species of heparin. Journal of Negative Results in BioMedicine, 2003, 2, 1.	1.4	8
167	Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. Virology, 2003, 307, 255-265.	2.4	120
168	Vaccinia virus-induced inhibition of nitric oxide production. Journal of Surgical Research, 2003, 111, 127-135.	1.6	6
169	Epsteinâ€“Barr virus and human hepatocellular carcinoma. Cancer Letters, 2003, 192, 49-57.	7.2	23
170	Preventing Neonatal HIV: A Review. Current HIV Research, 2003, 1, 321-327.	0.5	10
171	Unexpected similarity between the carboxyl termini of lentivirus and pestivirus envelope glycoproteins. Aids, 2003, 17, 276-277.	2.2	2
172	Avian dark cells. European Archives of Oto-Rhino-Laryngology, 2002, 259, 121-141.	1.6	7
173	Antibodies to Squalene in Recipients of Anthrax Vaccine. Experimental and Molecular Pathology, 2002, 73, 19-27.	2.1	47
174	Transmission of HCV to a chimpanzee using virus particles produced in an RNA-transfected HepG2 cell culture. Journal of Medical Virology, 2001, 65, 276-281.	5.0	18
175	Hepatitis C Viral Proteins Affect Cell Viability and Membrane Permeability. Experimental and Molecular Pathology, 2001, 71, 194-208.	2.1	19
176	Hepatitis C Virus Protein Expression Induces Apoptosis in HepG2 Cells. Virology, 2001, 282, 26-37.	2.4	33
177	Serum antibody testing in patients treated with intraocular silicone oil. Annals of Ophthalmology, 2001, 33, 53-55.	0.0	0
178	Inducible model to study negative strand RNA synthesis and assembly of hepatitis C virus from a full-length cDNA clone. Journal of Virological Methods, 2001, 94, 55-67.	2.1	26
179	HCV RNA levels in hepatocellular carcinomas and adjacent non-tumorous livers. Journal of Virological Methods, 2000, 90, 15-23.	2.1	20
180	Antibodies to Squalene in Gulf War Syndrome. Experimental and Molecular Pathology, 2000, 68, 55-64.	2.1	81

#	Article	IF	Citations
181	Reply. Experimental and Molecular Pathology, 2000, 68, 197-198.	2.1	4
182	Detection of Hepatitis C Virus RNA Sequences in B-Cell Non-Hodgkin Lymphoma. American Journal of Clinical Pathology, 2000, 113, 391-398.	0.7	35
183	Detection of exogenous and endogenous avian leukosis virus in commercial chicken eggs using reverse transcription and polymerase chain reaction assay. Avian Pathology, 1999, 28, 385-392.	2.0	16
184	Concentration-dependent differential induction of necrosis or apoptosis by HIV-1 lytic peptide 1. Peptides, 1999, 20, 1275-1283.	2.4	14
185	Viral induction, transmission and apoptosis among cells infected by a Human Intracisternal A-type retrovirus. Virus Research, 1999, 61, 19-27.	2.2	12
186	Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder. Biological Psychiatry, 1999, 45, 704-714.	1.3	44
187	Both necrosis and apoptosis contribute to HIV-1-induced killing of CD4 cells. Aids, 1999, 13, 1827-1839.	2.2	60
188	Effect of schistosomiasis and hepatitis on liver disease.. American Journal of Tropical Medicine and Hygiene, 1999, 60, 915-920.	1.4	44
189	Breast Implant Safety. Science, 1999, 283, 1641-1641.	12.6	0
190	Role of Potassium in Human Immunodeficiency Virus Production and Cytopathic Effects. Virology, 1998, 247, 189-199.	2.4	20
191	Lupus erythematosusâ€like features in patients with cutaneous Tâ€cell lymphoma. International Journal of Dermatology, 1998, 37, 579-585.	1.0	3
192	HERV-K10s and Immune-Mediated (Type 1) Diabetes. Cell, 1998, 95, 14-16.	28.9	38
193	Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet, The, 1998, 351, 1620-1624.	13.7	154
194	Inhibition of HIV Type 1 Production by Hygromycin B. AIDS Research and Human Retroviruses, 1998, 14, 885-892.	1.1	12
195	Reactivity of Sera from Systemic Lupus Erythematosus and Sjoì¨grenâ€™s Syndrome Patients with Peptides Derived from Human Immunodeficiency Virus p24 Capsid Antigen. Vaccine Journal, 1998, 5, 181-185.	2.6	40
196	A Synthetic Peptide Corresponding to the Carboxy Terminus of Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein Induces Alterations in the Ionic Permeability ofXenopus laevisOocytes. AIDS Research and Human Retroviruses, 1997, 13, 1525-1532.	1.1	40
197	Use of antipolymer antibody assay in recipients of silicone breast implants. Lancet, The, 1997, 349, 449-454.	13.7	54
198	Interaction of erythropoietin RNA binding protein with erythropoietin RNA requires an association with heat shock protein 70. Kidney International, 1997, 51, 579-584.	5.2	18

#	Article	IF	Citations
199	Biochemical Characterization of the Reverse Transcriptase of a Human Intracisternal A-Type Particle (HIAP). AIDS Research and Human Retroviruses, 1996, 12, 1367-1372.	1.1	4
200	Activity of Granzyme A, a Serine Protease in the Killing Granules of Cytotoxic T Lymphocytes, Is Reduced in Cells from HIV-infected Hemophiliacs. AIDS Research and Human Retroviruses, 1996, 12, 235-239.	1.1	5
201	Inhibition of Na+K+ATPase Activity in Membranes of Sindbis Virus-Infected Chick Cells. Virology, 1996, 216, 299-308.	2.4	13
202	Reduction of Human Immunodeficiency Virus Production and Cytopathic Effects by Inhibitors of the Na+/K+/2Clâ^'Cotransporter. Virology, 1996, 219, 291-294.	2.4	18
203	Antibodies against Retroviral Proteins and Nuclear Antigens in a Subset of Idiopathic CD4+T Lymphocytopenia Patients. AIDS Research and Human Retroviruses, 1996, 12, 931-940.	1.1	15
204	The interaction of a type A retroviral particle and class II human leukocyte antigen susceptibility genes in the pathogenesis of Graves' disease. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2271-2279.	3.6	24
205	Sequence Similarities between Latent Membrane Protein LMP-1 of Epstein-Barr Virus, Integral Membrane Protein p12^Iof Human T Cell Leukemia/Lymphotropic Virus Type 1, E5 Transformation Protein of Bovine Papillomavirus, and the Transmembrane Proteins of Slowly Transforming Retroviruses. AIDS Research and Human Retroviruses, 1995, 11, 431-432.	1.1	1
206	Evidence for a Retro Viral Trigger in Graves' Disease. Autoimmunity, 1995, 20, 135-142.	2.6	30
207	A General Model for the Surface Glycoproteins of HIV and Other Retroviruses. AIDS Research and Human Retroviruses, 1995, 11, 191-202.	1.1	113
208	Retroviruses and Their Roles in Chronic Inflammatory Diseases and Autoimmunity. , 1995, , 491-603.		19
209	Sequence Similarities between Retroviral Proteins and Components of the Spliceosome. AIDS Research and Human Retroviruses, 1994, 10, 521-522.	1.1	9
210	New evidence for involvement of retroviruses in sjÃ¶gren's syndrome and other autoimmune diseases. Arthritis and Rheumatism, 1994, 37, 465-469.	6.7	42
211	Viral burden in AIDS. Nature, 1993, 365, 301-302.	27.8	19
212	SjÃ¶gren's syndrome and assays for retroviral proteins: Reply. Arthritis and Rheumatism, 1992, 35, 1405-1405.	6.7	3
213	Tat contains a sequence related to snake neurotoxins. Aids, 1992, 6, 1541.	2.2	23
214	Membrane alterations linked to early interactions of HIV with the cell surface. Virology, 1992, 191, 941-946.	2.4	42
215	Similarities of viral proteins to toxins that interact with monovalent cation channels. Aids, 1991, 5, 1381-1384.	2.2	40
216	Concise Communications. Arthritis and Rheumatism, 1991, 34, 1336-1341.	6.7	48

#	Article	IF	Citations
217	Detection of p24 in HIV-1 infected cells embedded in LR White and Lowicryl K4M. The Histochemical Journal, 1991, 23, 381-384.	0.6	2
218	A Structural Correlation Between Lentivirus Transmembrane Proteins and Natural Cytolytic Peptides. AIDS Research and Human Retroviruses, 1991, 7, 511-519.	1.1	124
219	Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. Aids, 1990, 4, 553-558.	2.2	72
220	Early case of AIDS in the USA. Nature, 1990, 347, 509-509.	27.8	1
221	Detection of serum antibodies to retroviral proteins in patients with primary sjÃ¶gren's syndrome (autoimmune exocrinopathy). Arthritis and Rheumatism, 1990, 33, 774-781.	6.7	224
222	Extensive Antigenic Mimicry by Retrovirus Capsid Proteins. AIDS Research and Human Retroviruses, 1990, 6, 1361-1362.	1.1	42
223	A conserved idiotype and antibodies to retroviral proteins in systemic lupus erythematosus.. Journal of Clinical Investigation, 1990, 85, 1866-1871.	8.2	156
224	HIV Infection in 1968-Reply. JAMA - Journal of the American Medical Association, 1989, 261, 2199.	7.4	0
225	The role of monovalent cation transport in Sindbis virus maturation and release. Virology, 1989, 172, 42-50.	2.4	32
226	Alteration of intracellular monovalent cation concentrations by a poliovirus mutant which encodes a defective 2A protease. Virus Research, 1989, 13, 129-141.	2.2	11
227	A General Model for the Transmembrane Proteins of HIV and Other Retroviruses. AIDS Research and Human Retroviruses, 1989, 5, 431-440.	1.1	442
228	Potential mechanisms for the cytopathic properties of HIV. Aids, 1989, 3, 683-694.	2.2	65
229	Autogenous growth factor production by reticuloendotheliosis virus-transformed hematopoietic cells. Journal of Cellular Biochemistry, 1988, 37, 327-338.	2.6	1
230	Cell surface effects of human immunodeficiency virus. Bioscience Reports, 1988, 8, 35-48.	2.4	25
231	Documentation of an AIDS Virus Infection in the United States in 1968. JAMA - Journal of the American Medical Association, 1988, 260, 2085.	7.4	39
232	Sindbis virus infection increases hexose transport in quiescent cells. Virology, 1986, 155, 378-391.	2.4	20
233	Intracellular K+ and the expression of transformation parameters by chick cells transformed with the Bryan strain of Rous sarcoma virus. Virology, 1986, 150, 439-450.	2.4	8
234	Cell killing by ultraviolet-inactivated human immunodeficiency virus. Virology, 1986, 154, 395-400.	2.4	59

#	Article	IF	Citations
235	Alterations in monovalent cation transport in sindbis virus-infected chick cells. Virology, 1984, 132, 118-130.	2.4	52
236	Transformation parameters induced in chick cells by incubation in media of altered NaCl concentration. Virology, 1981, 111, 427-439.	2.4	41
237	Differential effects of ouabain on host-and sindbis virus-specified protein synthesis. Virology, 1979, 99, 179-182.	2.4	29
238	Na+ and K+ concentrations and the regulation of protein synthesis in Sindbis virus-infected chick cells. Virology, 1979, 96, 108-120.	2.4	139
239	Na+ and K+ concentrations and the regulation of the interferon system in chick cells. Virology, 1979, 96, 121-128.	2.4	41